CDXC - ChromaDex Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.0200
-0.0400 (-1.31%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.0600
Open3.0600
Bid0.0000 x 1200
Ask0.0000 x 1800
Day's Range2.9950 - 3.1208
52 Week Range2.7900 - 4.9500
Volume87,359
Avg. Volume221,618
Market Cap179.889M
Beta (3Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-0.5950
Earnings DateMar 6, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.17
Trade prices are not sourced from all markets
  • GlobeNewswire

    ChromaDex Statement Regarding the October 9th Order in the Central District of California Litigation

    ChromaDex Corp. (CDXC) issued the following statement. Through discovery, we learned of egregious behavior by Elysium related to the theft of trade secrets and confidential information including text messages revealing unethical conduct and a stated intention to “destroy” ChromaDex. In his order, the judge seeks additional information about how ChromaDex was damaged by the theft, and we look forward to answering his questions.

  • GlobeNewswire

    Humanitarian Grant Awarded for Preclinical Study on the Impact of NAD Precursor Vitamins on Milk Bioactive Production and Brain Development in Rodents

    Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, receives a research grant from the Bill & Melinda Gates Foundation to study the effects of NAD-boosting supplements on the production of bioactive factors in milk and the effect of the supplements on brain development in animals. Dr. Brenner explained that his previous research indicated that a new mother’s body does everything in its power to provide for the needs of her offspring: mobilizing her own protein, fat and carbohydrate to make milk, mobilizing her own NAD precursors for the offspring, and producing bioactive factors important for the  brain and physical development of her offspring. The new mother’s body does so much that she experiences postpartum as a metabolic stress.

  • GlobeNewswire

    ChromaDex to Present at the 5th Annual B. Riley FBR Consumer and Media Conference

    LOS ANGELES, Sept. 26, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present.

  • Industry Leaders Aubrey De Grey And Frank Jaksch Join Yuva Biosciences Advisory Board
    PR Newswire

    Industry Leaders Aubrey De Grey And Frank Jaksch Join Yuva Biosciences Advisory Board

    BIRMINGHAM, Ala., Sept. 10, 2019 /PRNewswire/ -- Yuva Biosciences, Inc., an anti-aging company developing cosmeceuticals as well as pharmaceuticals targeted at aging-associated hair loss, wrinkled skin, and reduced energy, today announced that Aubrey de Grey, Ph.D. and Frank L. Jaksch, Jr. have joined the Company's Advisory Board. "We are thrilled to have two of the pioneering thinkers in the industry, Aubrey de Grey and Frank Jaksch, join our Advisory Board," said Greg Schmergel, Chairman at Yuva Biosciences.

  • Thomson Reuters StreetEvents

    Edited Transcript of CDXC earnings conference call or presentation 7-Aug-19 8:30pm GMT

    Q2 2019 Chromadex Corp Earnings Call

  • GlobeNewswire

    ChromaDex Announces $7 Million Private Placement of Common Stock

    ChromaDex Corp. (CDXC) announced today that it has entered into a securities purchase agreement for the sale of $7.0 million of its common stock in a private placement. The private placement was led by new strategic investors. The private placement is expected to close on or about August 15, 2019, subject to the satisfaction of customary closing conditions.

  • ChromaDex Corporation (CDXC) Q2 2019 Earnings Call Transcript
    Motley Fool

    ChromaDex Corporation (CDXC) Q2 2019 Earnings Call Transcript

    CDXC earnings call for the period ending June 30, 2019.

  • ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates

    ChromaDex (CDXC) delivered earnings and revenue surprises of 15.38% and 2.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    ChromaDex Receives Positive Opinion on Nicotinamide Riboside as a Novel Food from the World-Leading European Food Safety Authority (EFSA)

    ChromaDex Corp. (CDXC) today announced that the European Food Safety Authority (EFSA) has issued a positive opinion on Nicotinamide Riboside (NR) as a novel food ingredient for use in a food supplement at a daily serving of 300mg for the healthy adult population, a critical step in the EU regulatory approval process. “Safety is paramount for ChromaDex and this positive opinion from EFSA underscores our depth of science, and is the latest in a consistently positive series of reviews of NR by authoritative bodies,” said ChromaDex CEO Rob Fried.

  • GlobeNewswire

    ChromaDex Corporation Reports Second Quarter 2019 Financial Results   

    Second Quarter 2019 Highlights vs. Second Quarter 2018 Strong growth in net sales to $11.1 million, significantly higher gross margins, and improved marketing.

  • GlobeNewswire

    ChromaDex Adds Top Talent to its Leadership Team

    ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today three strategic hires to its executive team. Joining the company are Megan Jordan as Chief Communications Officer & Senior Vice President of Global Corporate Affairs, Dr. Andrew Shao as Vice President of Scientific & Regulatory Affairs, and Alberto Bottene as Senior Vice President of Sales and Business Development.

  • ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
    Zacks

    ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    ChromaDex to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019

    LOS ANGELES, July 31, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., August 7, 2019 at 4:30 p.m. Eastern time to discuss its.

  • GlobeNewswire

    TRU NIAGEN® Expands Canadian Retail Footprint with Distribution at Whole Foods Ontario Locations

    ChromaDex Corp. (CDXC) announced today its flagship consumer product, Tru Niagen® (nicotinamide riboside) is now available in all seven Whole Foods Market locations across Ontario, in addition to select Pure Pharmacy locations, Fullscript Canada, and online. Tru Niagen joins Whole Foods as the store’s newest product in the energy category based on its strong clinical results and scientific research.

  • GlobeNewswire

    ChromaDex Appoints Scripps Research Professor of Molecular Medicine, Brunie H. Felding, PhD, to the Scientific Advisory Board

    ChromaDex Corp. (CDXC) announced today it has appointed Brunie H. Felding, Ph.D., Associate Professor, Department of Molecular Medicine, Scripps Research Institute, California Campus, to the Scientific Advisory Board (SAB). The group of scientists Dr. Felding leads at Scripps has conducted research that has shown that increasing NAD+ with the B3 vitamin nicotinamide prevented breast cancer development in mice.

  • Benzinga

    ChromaDex Shares Nicotinamide Riboside Study Results

    ChromaDex Corp (NASDAQ: CDXC ) announced the results of its latest clinical study were published in the journal Scientific Reports. The study further validates the safety and efficacy of ChromaDex’s proprietary ...

  • GlobeNewswire

    Newly Published Nicotinamide Riboside Study Further Demonstrates Safety of Sustained Niagen Supplementation and Optimal Dosing Levels

    ChromaDex Corp. (CDXC) announced today that the results of its latest clinical study were published Friday in the journal Scientific Reports. The largest trial of nicotinamide riboside (NR) published to date, the new study further validates the safety and efficacy of ChromaDex’s proprietary form of NR, Niagen®. “The results of this large human trial directly support the efficacy and safety of our NAD-boosting consumer product Tru Niagen,” says ChromaDex CEO Rob Fried.

  • GlobeNewswire

    TRU NIAGEN® Awarded ‘Ingredient of the Year: Healthy Aging’ by NutraIngredients-USA

    ChromaDex Corp. (CDXC) announced today its flagship consumer product, Tru Niagen® (nicotinamide riboside) received the ‘Ingredient of the Year: Healthy Aging’ award at the NutraIngredients-USA Awards in New Orleans on June 3, 2019. “We are grateful to the judges for recognizing the quality of the science, the safe production processes, and the regulatory depth behind Tru Niagen in our efforts to support cellular health and healthy aging,” says ChromaDex CEO Rob Fried.

  • Thomson Reuters StreetEvents

    Edited Transcript of CDXC earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Chromadex Corp Earnings Call

  • GlobeNewswire

    ChromaDex to Present at the 20th Annual B. Riley FBR Investor Conference

    ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20th Annual B. Riley FBR Investor Conference at the Beverly Hilton Hotel in Beverly Hills, CA. The ChromaDex management team is scheduled to present on Wednesday, May 22, at 1:30 p.m. Pacific Time.  ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day. ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients.

  • ChromaDex Corporation (CDXC) Q1 2019 Earnings Call Transcript
    Motley Fool

    ChromaDex Corporation (CDXC) Q1 2019 Earnings Call Transcript

    CDXC earnings call for the period ending March 31, 2019.

  • ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates

    ChromaDex (CDXC) delivered earnings and revenue surprises of 0.00% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    ChromaDex: 1Q Earnings Snapshot

    The Los Angeles-based company said it had a loss of 15 cents per share. Losses, adjusted for stock option expense, were 11 cents per share. The natural products company posted revenue of $10 million in ...

  • GlobeNewswire

    ChromaDex Corporation Reports First Quarter 2019 Financial Results

    - First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million - First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net.

  • GlobeNewswire

    ChromaDex Announces $10 Million Issuance of Convertible Notes

    ChromaDex Corp. (CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement.  The transaction was led by international strategic investors. The transaction is expected to close on or about May 17, 2019, subject to the satisfaction of customary closing conditions. The convertible notes will automatically convert into shares of ChromaDex common stock 45 days following the closing.  The convertible notes will convert at $4.59 per share (market closing price on May 7, 2019), or if a common stock financing occurs in the 45 day period following the closing with a purchase price of less than $4.59 per share, at the price per share at which shares are issued in that financing.